Pharmaceuticals Company Research Reports

Nutritional Holdings Ltd Fundamental Company Report provides a complete overview of the company’s affairs.

Bioalpha Holdings Bhd Fundamental Company Report provides a complete overview of the company’s affairs.

... Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape Develop and design ...

... Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape Develop and design in-licensing and ...

... pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development ...

The 2014 U.S. Medical Equipment & Supplies Mfg. Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry ... , inventories, rentals, and other expenses nationally and for all 50 U.S. States and up to 900 metro areas. Expenses categories include materials used ...

... test that all antisense/ RNAi focused companies have to pass. ISIS has a robust cash position, valuable IP assets, and success of a few ... in the current pipeline could accelerate the transformation from a discovery to a pharma company and help it to grow beyond KYNAMRO.

... this will take time. Leveraging Balance sheet for Acquisition Consolidation of recent acquisitions (URL and DUSA) as well as management’s quest for new ... in US. Management has commented that Sun Pharma will continue to seek acquisitions in US (focus on Derma) and other emerging markets with small to medium ...

... complex generics to drive growth. In other words, balance sheet would remain the biggest growth driver, both for ... generics are dwindling. DUSA acquisition looks very attractive for Sun Pharma due to (1) DUSA is acquired at a trailing EV / Operating ... of Rs.795 and reiterate our Outperform rating on the stock.

BIOCON - Market Perform, Result helped by unsustainable other income We reiterate our Market Perform rating on Biocon despite the Q2 FY13 result being higher than our estimates. ... values Syngene at ~11x EV/EBITDA – 16% higher than Biocon’s market valuation. We keep our estimate unchanged. We now rollover our ...

INDIA PHARMA Sub: DR REDDY’S LAB - Market Perform, Great Result, Still Growth to Remain Modest We reiterate our Market Perform rating on DRRD with an upward ... our estimate largely due to high growth in the US generics market business (17% Q-o-Q, constant currency). Other expenses remained lower sequentially ...

... Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside Abstract 3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD ... , please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”. Report type – Deep ...

Abstract Alexion (ALXN) products lack any near term competition ... products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying ... read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”

INDIA PHARMA Subject: IPCA – Outperform, Momentum Continues We reiterate our Outperform on Ipca post its Q2 ... forward sales growth will be driven by (1) continuing growth in the anti malarial tender business to WHO ... to US likely from FY13 and (3) continuing growth from India and other branded markets. While we ...

INDIA PHARMA Subject: LUPIN - Market Perform, Margin worry on base business Lupin’s Q2FY13 result was largely inline with our estimates, however, ... R&D expense. Ex-branded US generic sales declined sequentially despite Combivir gaining market share in Q2 FY13. All these indicate pressure on the US base ...

... core business, bonus upside from positive data of IVIG in AD, and an attractive risk-reward profile, Grifols SA (GRF) is our preferred choice among three ... coverage initiation report released on 22nd Oct., 2012 on GRF titled, “GRIFOLS SA - IVIG Opportunity in AD - Dark Knight”.

... report analyzes the worldwide markets for Medical Laboratories in US$ Million by the following Product Segments: Hospital-Based Medical Laboratories, and Others. The ... through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 162 companies including many key and ...

... events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in ... Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST ... on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”

... read our report released on May 31st, 2012 on ONXX, titled “ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?”

At ACC, Merck reported final detailed results on Vorapaxar from the TRA 2°P- ... a prior history of MI (2/3 patient population), where Vorapaxar reduced death/stroke/MI events by 140, while the number ... therapy, we do not see meaningful sales for Vorapaxar. Merck is yet to decide on whether to file this drug ...

... Bayer for Japan royalties made FY11 a profitable year for Onyx pharma (ONXX), we do not expect it to be sustainable as high operating expenses (h43% YoY ... detail, please read our report released on 2nd Mar., 2012 on Onyx Pharma titled “Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!”

Recent news about “possible acquisition of Onyx pharma” is not a surprise in light of the upcoming ... over Regorafenib (BAY73-4506, PhIII) with Bayer. Onyx product pipeline focuses only in oncology. We have ... released on 30th November, 2011 on Onyx pharma titled “M&A Rumors Fuel Investors Interest and Stock ...

As expected, Sun Pharma received the final approval for generic Cardizem CD (annual sales of $300m) for all the strengths, viz. 120 mg, ... the patented price. All the current generic companies including Sun pharma has settled the Para IV litigation with Valeant (erstwhile Biovail ...

... daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises ... NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the ... IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN ...

... , detection, gene profiling, and expression, polymorphism, screening, protein interaction networks, and others. Sequencing is expected to continue playing a major role in clinical laboratories, e.g., in detecting resistance mutations in viruses and bacteria, especially because of the rising availability of ...

Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...

Pharmasset (VRUS) has created immense value for its shareholders by promising ... more detail, please read our note released on 28th July on Pharmasset titled “Poised to Deliver the Best Oral Option Against HCV Infection”.

Our recent study about the Cardizem CD Para IV litigation between Sun Pharma and Valeant ( ... 2012 (2) there is currently no competition for 360mg Cardizem CD and Sun Pharma will be the only generic ... Sun will be able to launch the generic of Cardizem CD upon receiving final USFDA approval including the launch ...

Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ $7.8b) are Gleevec, Namenda, Comtan, ...

The Medical Laboratories Industry-Jobs & Wages report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics on industry job titles, fr...